Loading...
•
Jun 30, 2021
Neurocrine Biosciences Q2 2021 Earnings Report
Reported sustained growth for INGREZZA and advancements in the R&D pipeline.
Key Takeaways
Neurocrine Biosciences reported second quarter 2021 financial results, highlighting sustained growth for INGREZZA with net product sales of $265 million and approximately 48,900 total prescriptions. The company is also advancing its R&D pipeline with 9 mid-to-late-stage clinical trials planned for this year.
INGREZZA net product sales reached $265 million in Q2 2021 with approximately 48,900 total prescriptions.
Record total prescriptions were achieved during the second quarter 2021, reflecting increased commercial activities.
New prescriptions increased throughout the second quarter, reaching their highest levels since March 2020 despite continued significant use of telemedicine within psychiatry.
Second quarter refill rates per patient returned to historical normal range versus seasonally low first quarter levels.
Neurocrine Biosciences
Neurocrine Biosciences
Neurocrine Biosciences Revenue by Segment
Revenue by Segment
INGREZZA Revenue
CapyFin.com Forward Guidance
Neurocrine Biosciences reaffirms its full-year 2021 expense guidance, with combined GAAP R&D and SG&A expenses expected to be in the range of $855 million to $905 million, and combined Non-GAAP R&D and SG&A expenses expected to be in the range of $720 million to $770 million.
Positive Outlook
- Continued success of INGREZZA
- Advancement of clinical programs
- Potential benefits from collaborative partnerships
- Ability to adapt business to the evolving COVID-19 pandemic
- Mitigation of COVID-19 impact on the business
Challenges Ahead
- Future financial and operating performance
- Risks associated with commercialization of INGREZZA and ONGENTYS
- Impact of the evolving COVID-19 pandemic
- Dependence on third parties for development and manufacturing activities
- Potential adverse decisions by the FDA or other regulatory authorities